A Single Dose, Randomized, Open-label, Two-way Crossover Food-effect Bioavailbility Study of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin 50/10/1000 mg Sustained Release Tablets Under Fasting and Fed Conditions in Healthy Volunteers
Latest Information Update: 13 Feb 2026
At a glance
- Drugs Dapagliflozin/gemigliptin/metformin (Primary)
- Indications Unspecified
- Focus Pharmacokinetics
- Sponsors LG Chem
Most Recent Events
- 13 Feb 2026 New trial record